Australia's most trusted
source of pharma news
Wednesday, 18 June 2025
Posted 4 June 2025 PM
Arrotex is targeting a huge market with its latest innovative product to hit the PBS, a powerful treatment for skin treatments that are resistant to lower potency topical treatments.
Xobet will be the most potent PBS-listed topical corticosteroid indicated for corticosteroid-responsive dermatoses that are resistant to lower potency topical corticosteroid therapy after being listed in May.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.